Sutro Biopharma (STRO) is trading down at $15.13 (-1.43%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Sutro Biopharma revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $59.7M | $51.7M | $38.4M | $42.7M | $42.7M | $61.9M | $67.8M | $153.7M | $62.0M | $102.5M |
| Growth (year over year) | — | −13.4% | −25.7% | +11.2% | −0.0% | +44.8% | +9.5% | +126.8% | −59.6% | +65.2% |
| Operating income | $1.36M | −$19.3M | −$37.2M | −$55.5M | −$71.1M | −$98.5M | −$128.9M | −$89.3M | −$238.5M | −$158.4M |
| Operating margin | 2.3% | −37.2% | −96.9% | −129.8% | −166.3% | −159.2% | −190.3% | −58.1% | −384.3% | −154.5% |
| Net income | $1.70M | −$19.7M | −$35.3M | −$119.2M | −$32.1M | −$105.5M | −$119.2M | −$106.8M | −$227.5M | −$191.1M |
| Net margin | 2.8% | −38.1% | −91.9% | −278.9% | −75.2% | −170.6% | −175.9% | −69.5% | −366.6% | −186.5% |
| EPS (diluted) | $0.00 | −$4395.00 | −$613.00 | −$243.00 | −$9.90 | −$22.90 | −$23.50 | −$17.80 | −$29.40 | −$22.49 |
| Balance sheet | ||||||||||
| Cash and equivalents | $11.6M | $22.0M | $125.3M | $4.96M | $206.2M | $30.4M | $47.3M | $69.3M | $190.3M | $58.1M |
| Total assets | — | $40.8M | $223.1M | $156.4M | $394.1M | $341.4M | $406.9M | $470.7M | $387.2M | $173.8M |
| Total liabilities | — | $47.3M | $91.6M | $58.6M | $62.1M | $88.8M | $189.9M | $321.1M | $342.6M | $306.3M |
| Long-term debt | — | — | $10.0M | $8.88M | $24.5M | $15.7M | $3.77M | $0 | — | — |
| Shareholders' equity | −$90.9M | −$109.0M | $131.5M | $97.8M | $332.0M | $252.6M | $217.0M | $149.6M | $44.6M | −$132.5M |
| Cash flow | ||||||||||
| Operating cash flow | −$13.2M | −$37.1M | $12.7M | −$65.0M | −$67.8M | −$81.7M | $3.55M | −$111.6M | −$191.5M | −$177.2M |
| Capital expenditure | $4.39M | $3.32M | $1.56M | — | — | — | — | — | — | — |
| Free cash flow | −$17.5M | −$40.4M | $11.1M | — | — | — | — | — | — | — |
| Share buybacks | — | — | — | — | — | $7.00K | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.52M | $14.8M | $17.4M | $63.7M | $9.69M | $11.6M | $14.5M | $9.84M |
| Growth (year over year) | −49.7% | — | +33.8% | +148.0% | +13.8% | −21.4% | −16.5% | −84.6% |
| Operating income | −$67.9M | −$65.3M | −$68.5M | −$3.35M | −$48.5M | −$38.0M | −$29.7M | −$29.9M |
| Operating margin | −797.2% | −440.7% | −393.8% | −5.2% | −499.9% | −326.7% | −204.2% | −303.8% |
| Net income | −$48.8M | −$72.4M | −$76.0M | −$11.5M | −$56.9M | −$46.8M | −$38.5M | −$38.5M |
| Net margin | −572.6% | −489.2% | −436.6% | −18.0% | −586.6% | −401.5% | −265.0% | −391.6% |
| EPS (diluted) | −$5.90 | −$11.70 | −$9.08 | −$1.35 | −$6.70 | −$5.36 | −$2.94 | −$2.33 |
| Balance sheet | ||||||||
| Cash and equivalents | $174.6M | $190.3M | $106.2M | $64.0M | $65.9M | $58.1M | $73.7M | $54.3M |
| Total assets | $451.8M | $387.2M | $321.4M | $262.4M | $209.7M | $173.8M | $242.0M | $194.5M |
| Total liabilities | $340.6M | $342.6M | $347.2M | $294.5M | $296.9M | $306.3M | $308.9M | $297.8M |
| Shareholders' equity | $111.2M | $44.6M | −$25.8M | −$32.1M | −$87.3M | −$132.5M | −$66.9M | −$103.3M |
| Cash flow | ||||||||
| Operating cash flow | −$64.5M | −$71.7M | −$67.9M | −$44.7M | −$38.2M | −$26.4M | −$42.3M | −$38.3M |
From Sutro Biopharma's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Sutro Biopharma
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Source: Wikipedia — Sutro Biopharma
- Headquarters
- South San Francisco, California From SEC filings, Oct 2026
Recent News
No recent news mentioning Sutro Biopharma in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International